Sunday, October 16, 2022 3:43:22 PM
Fireman,
The one thing that an official TLD statement does is allow the most recent lender to the company to convert the loan to stock under favorable conditions on the next offering. I would hope that no such offering is made until after much is known, and the stock is considerably higher, but releasing the official statement would in some ways handcuff the company.
I believe that when things start to happen much will happen in a matter of weeks. I believe it will all start with the Journal, but we'll see, there are possible other triggers as well. As I see it, if the company issues an official TLD statement after Dr. Liau's Abstract is revealed, or after her presentation it would be considered the peer reviewed event needed to end the quiet period. If that occurred without the Journal being issued I don't think they'd have to abandon the Journal, but it would be an indication that they feel they cannot wait any longer.
Gary
The one thing that an official TLD statement does is allow the most recent lender to the company to convert the loan to stock under favorable conditions on the next offering. I would hope that no such offering is made until after much is known, and the stock is considerably higher, but releasing the official statement would in some ways handcuff the company.
I believe that when things start to happen much will happen in a matter of weeks. I believe it will all start with the Journal, but we'll see, there are possible other triggers as well. As I see it, if the company issues an official TLD statement after Dr. Liau's Abstract is revealed, or after her presentation it would be considered the peer reviewed event needed to end the quiet period. If that occurred without the Journal being issued I don't think they'd have to abandon the Journal, but it would be an indication that they feel they cannot wait any longer.
Gary
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
